subscribeSubscribe
Genentech`s Biologic Lucentis (ranibizumab) Receives Approval in the U.S.

Genentech`s Biologic Lucentis (ranibizumab) Receives Approval in the U.S.
FDA
15 Feb 2024
Share Share
Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M

Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M
FIERCE PHARMA
22 Jan 2024
Share Share
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
GLOBENEWSWIRE
04 Oct 2023
Share Share
Ranibizumab Launch Midas Pharma is the Marketing Authorisation Holder (MAH) of a biosimilar

Ranibizumab Launch Midas Pharma is the Marketing Authorisation Holder (MAH) of a biosimilar
PRESS RELEASE
25 Sep 2023
Share Share
FDA rejected Outlook Therapeutics` Lucentis rival, & the company`s stock plunged

FDA rejected Outlook Therapeutics` Lucentis rival, & the company`s stock plunged
Nicole DeFeudis ENDPTS
31 Aug 2023
Share Share
STADA Arzneimittel`s Ximluci (Ranibizumab) Receives Approval in Europe

STADA Arzneimittel`s Ximluci (Ranibizumab) Receives Approval in Europe

EMA
20 Jun 2023
Share Share
Samsung`s Biologic Byooviz (Ranibizumab) Receives Approval in the U.S.

Samsung`s Biologic Byooviz (Ranibizumab) Receives Approval in the U.S.
FDA
16 Jun 2023
Share Share
FDA issues new guidance on wet AMD drug development

FDA issues new guidance on wet AMD drug development
Paul Schloesser ENDPTS
03 Mar 2023
Share Share
Roche, Novartis Win Appeal Against Record French Fine

Roche, Novartis Win Appeal Against Record French Fine
BARRONS
17 Feb 2023
Share Share
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI
GLOBENEWSWIRE
13 Feb 2023
Share Share